Roche Holding AG (RHHBY)

OTCMKTS: RHHBY · Delayed Price · USD
30.59
-0.37 (-1.20%)
Apr 12, 2024, 3:59 PM EDT - Market closed
Market Cap 198.37B
Revenue 66.11B
Net Income 13.52B
Shares Out 6.48B
EPS 1.99
PE Ratio 15.40
Forward PE 12.74
Dividend $1.39 (4.55%)
Ex-Dividend Date Mar 14, 2024
Volume 2,368,078
Open 30.89
Previous Close 30.96
Day's Range 30.55 - 30.96
52-Week Range 30.06 - 40.48
Beta 0.15
Analysts Hold
Price Target 40.00 (+30.76%)
Earnings Date n/a

About RHHBY

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]

Sector Healthcare
Founded 1896
Employees 103,605
Stock Exchange OTCMKTS
Ticker Symbol RHHBY
Full Company Profile

Financial Performance

In 2023, RHHBY's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 12.36 billion, a decrease of -8.67%.

Financial numbers in CHF Financial Statements

Analyst Forecast

According to one analyst, the rating for RHHBY stock is "Hold" and the 12-month stock price forecast is $40.0.

Price Target
$40.0
(30.76% upside)
Analyst Consensus: Hold

News

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

Basel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This...

2 days ago - GlobeNewsWire

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low status may now be eligible for HER2-targeted treatment, which could significa...

3 days ago - PRNewsWire

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

4 days ago - Barrons

Veracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive Officer

BURLINGTON, Mass.--(BUSINESS WIRE)-- #AI--Brian Roche has been appointed CEO at Veracode. His ascension from Chief Product Officer completes a succession plan, which sees Sam King step down.

10 days ago - Business Wire

Lido Advisors' Gina Sanchez offers 3 buys and a bail: Roche, TotalEnergies, AB InBev & Arm

Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three buys and a bail, including Roche, TotalEnergies, AB InBev, and Arm.

Other symbols: BUDTTEARM
15 days ago - CNBC Television

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

Basel, 26 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of the cobas® Malaria test for use on the cobas® 6800/8800 Systems. This ...

18 days ago - GlobeNewsWire

The bottom of interest rate in the new cycle will be much higher: David Roche and Euan Munro

Euan Munro of Newton Investment and David Roche of Independent Strategy discuss the possibility of the Federal Reserve reducing interest rates against the backdrop of high government spending and budg...

19 days ago - CNBC International TV

David Roche says India won't replace China in global trade

David Roche, president and global strategist at Independent Strategy, says China may be stagnating, but it's "stagnating at a later stage of development than India."

22 days ago - CNBC International TV

Roche Annual General Meeting 2024

Basel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders...

4 weeks ago - GlobeNewsWire

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for use in laboratories and point of care services navify Analytics provides op...

4 weeks ago - PRNewsWire

Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Other symbols: ALNY
5 weeks ago - Reuters

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

Basel, 05 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [ NCT05103332 ] of zilebesiran, an investigational RNAi therapeutic in developmen...

5 weeks ago - GlobeNewsWire

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

6 weeks ago - Market Watch

Roche explores selling lung disease drug, Bloomberg reports

Roche is considering selling its lung disease drug Esbriet, Bloomberg News reported on Monday citing people with knowledge of the matter.

6 weeks ago - Reuters

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the effi...

6 weeks ago - GlobeNewsWire

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsore...

6 weeks ago - Business Wire

Roche's Xolair reduces reactions to severe food allergies in study

Xolair, a 20-year-old asthma drug sold by Roche and Novartis , significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sun...

6 weeks ago - Reuters

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Basel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions,...

2 months ago - GlobeNewsWire

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair®...

2 months ago - Business Wire

Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains

Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...

Other symbols: ASMLAZNGSKNVONVSSAPSNY
2 months ago - Bloomberg Markets and Finance

Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algor...

2 months ago - PRNewsWire

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

Other symbols: ASMLAZNGSKNVONVSSAPSNY
2 months ago - Barrons

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

Other symbols: ASMLAZNGSKNVONVSSAPSNY
2 months ago - Market Watch

Roche cutting 345 jobs in product development - media

Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.

2 months ago - Reuters

Roche forecasts return to growth in 2024 as it overcomes drop in COVID sales

Roche said on Thursday that 2024 would see a return to sales growth as it is overcoming a slump in demand for its COVID-19 products and the sales decline of a trio of established cancer drugs is abati...

2 months ago - Reuters